Literature DB >> 11421380

Clinical trial of sequential treatments of moderately severe and severe malaria with dihydroartemisinin suppository followed by mefloquine in Thailand.

P Wilairatna1, S Krudsood, U Silachamroon, P Singhasivanon, S Vannaphan, S Faithong, M Klabprasit, S N Bangchang, P Olliaro, S Looareesuwan.   

Abstract

One hundred and fifty patients with severe falciparum malaria were administered sequential combination of dihydroartemisinin suppository followed by an oral mefloquine tablet. Dihydroartemisinin suppositories (80 mg/capsule) were given rectally once daily for 3 days with a total dose of 8-10 mg/kg. Two doses of mefloquine, 15 mg/kg/dose and 10 mg/kg/dose, were given at 72 hr and 84 hr, respectively. The mean [SD] parasite clearance time and fever clearance time were 46.1 [15.7] hr and 82.5 [59.6] hr, respectively. No death or major adverse drug effects occurred. The cure rate at 28 days of inpatient follow-up was 95% (113 of 119 patients). In severe malaria, dihydroartemisinin suppository followed by oral mefloquine is a suitable alternative treatment to parenteral drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11421380

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  2 in total

Review 1.  Management of malaria in Thailand.

Authors:  Udomsak Silachamroon; Srivicha Krudsood; Nanthaphorn Phophak; Sornchai Looareesuwan
Journal:  Korean J Parasitol       Date:  2002-03       Impact factor: 1.341

Review 2.  Prevalence of Signs of Severity Identified in the Thai Population with Malaria: A Systematic Review and Meta-Analysis.

Authors:  Wanida Mala; Polrat Wilairatana; Chutharat Samerjai; Frederick Ramirez Masangkay; Kwuntida Uthaisar Kotepui; Manas Kotepui
Journal:  Int J Environ Res Public Health       Date:  2022-01-21       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.